but the truth is, it took three days to develop these mrna vaccines. can we expect that because of that extraordinary technology, if there are new variants, we will be able to go back to the mrna process, and within a few days, have a new vaccine for that variant? >> the mrna technology, fareed, has been getting developed for more than two decades. so in a way it was a just-in-time availability of this very powerful technology, and yes, it should be easier within days to weeks to develop new tweaks to the vaccine that address new variants if those arise. and it may even be possible to use mrna technologies to protect against other viruses, including influenza. so it's an exciting new development. they're remarkably effective, they're extremely safe and they've been available in record time. the tragedy is, first, that so many people in the u.s. and some other countries have access to them and aren't getting them, and many will die as a result. and that so many people who want them and need them don't have access yet. and as a world, we have to fix that

i got the mrna vaccine. when it came out people were hesitant about that technology. and there are probably millions of americans that got it only because it was a single dose. so i would say now is take the vaccine in front of you. i would take the two doses of the mrna vaccine and i think two doses will show to be better than the one. but i think if a second j&j dose is good enough to boost the response. that is what you could be a candidate soon you may feel more protected, but you're not at risk to get very sick you are still a healthy young person that has been vaccinated. you should have some reassurance that maybe you mask up more in your community, maybe you don't go indoors to restaurants, add a few more barriers to you and unvaccinated people, but it should not feel like a zero sum gain here. because you're not. >> i guess there is another aspect of this, which is, and yesterday as i was watching part of the hearing and we saw rochelle rowinski. so they say they're looking at data, they have not made a determination. how long will it take for them to make a

i think certainly the mrna _ buy vaccines the future?nly the mrna technology, that is one of its major limitations, although we have learned that the last year that these vaccines are more stable than we originally thought but nevertheless the low temperature storage they need for longer periods is a limiting step, particularly for countries who do not have those kinds of freezing facilities. ., , ,., not have those kinds of freezing facilities. ., , ~ ., facilities. professor adam finn, thank you _ facilities. professor adam finn, thank you very _ facilities. professor adam finn, thank you very much _ facilities. professor adam finn, thank you very much for - facilities. professor adam finn, thank you very much for your i facilities. professor adam finn, i thank you very much for your time. thank you. cuba is preparing to evacuate residents along its southern coast amid fears that tropical storm elsa could wreak havoc on the island. the storm has already left a trail of destruction through the eastern caribbean, killing a young boy and

the question then obviously arises, the direct data we have from the mrna vaccines. what about jay and jay, the question isoften asked . is indirect evidence for effectiveness of j&j against the delta variance. the reason is that the effectiveness of this vaccine is similar to a vaccine for which we do have data. namely the az area the data that i just showed you. since these vaccines, the az and j and j are based on very similar forms, one could anticipate and make a reasonable assumption that the results against the delta variance would be at least similar, perhaps even better. we're now looking at neutralization data and soon we will have more firm data which we will make available to you as soon as it occurs. next slide area another question commonly asks is the who concerned about the delta variance and urging vaccinated people to keep wearing masks. there's a reason for that area the who is responsible for the planet as a whole. it is different in the world in general from here in the united states. next slide. as shown if you look at the share of the populatio

>> the two mrna vaccines, the pfizer vaccine and the moderna vaccine, are essentially identical in my mind, and they're probably the best vaccines we have right now in terms of efficacy against the delta variant. the data on johnson & johnson is just much less clear. there is enough data out there in my mind to suggest that the j&j vaccine is still going to do a very, very good job of protecting against severe illness and death. the question is, how good a job is it going to do against preventing breakthrough infection, symptomatic infections? and the short answer is we just don't know, and we'll know more in the upcoming weeks. the thing that i worry about are the chinese vaccines, which have been used maybe about 1/3 to 1/2 of all the vaccines in the world so far have been the vaccines made in china. again, we don't have a lot of data on them, but the data we have suggests that they're far, far less effective against the delta variant. that worries me, because it means a lot of the world that's been vaccinated is actually potentially quite still vulnerable to the delta variant. >> y

and the mrna vaccines. what about j&j, a question often asked. there's indirect evidence for effectiveness of j&j against the sars co scrmbings-2 delta variant. the reason is that the effectiveness of this vaccine, similar to a vaccine for which we do have data, namely, the a.z., the data that i just showed you. since these vaccines, the a.z. and the j&j are based on very similar platforms. one could anticipate and make a reasonable assumption that the results against the delta variant would be at least similar, perhaps even better. we are now looking at neutralization data and soon we will have more firm data which we will make available to you as soon as it occurs. next slide. another question commonly asked is the w.h.o., concerned about the delta variant, has urged vaccinated people to keep wearing masks. there's a reason for that. the w.h.o. is responsible for the planet as a whole. it's different in the world in general from here in the united states. next slide. as shown here, if you look at the share of the population fully vaccinated in

ran really low on the astrazeneca vaccine, they frequently, the people get the second dose with an mrna vaccine, including last week, merkel got her second vaccine. so, it is really common usage there. >> so, we do not you know yet if the cdc will make that recommendation, but your question here from bath. she said, i received the one dose johnson & johnson with the delta variant, she was wondering if she should get one shot of pfizer or moderna. is that even possible right now? could she just go and do it? >> not if she gives that history, i don't think. people can do what people can do. what i would do is hang tight and see what cdc recommends, unless you have some sort of underlying immunosuppression or taking drugs, cdc will have an advisory committee that meets tomorrow to review whether people in the 2% to 4% of adults that either have the solid organ transplants or under immunosuppressive therapy for any right of things, should receive a additional dose. a third dose of either pfizer or moderna or an additional dose of the j&j vaccine. so the question between switching may well c

it's a miracle that we got the mrna vaccines done so quickly.f the angst right now because this is all happening so fast unlike a slower process of previous pandemics? >> it may be part of it because mrna vaccines do give you that great advantage to make a vaccine candidate within hours or weeks. i think the lightning speed of this which was one of the advantages has been something people have exploited to say this happened too quickly. imagine if we were still waiting the old way. how many more hundreds of thousands of people would have died, how many illnesses would have happened. i think the speed of the mrna vaccine is what makes them the most attractive thing about them and it's probably going to change the way we face infectious disease outbreaks in the future forever. it's a huge advantage we now have as humans against the viral kingdom. jonathan: thank you for your hard work. don't mess at the end of a very long shift i'm sure. -- joining us at the end of a very long shift i'm sure. on the equity market, the s&p 500 -10. down .2% on the

mrna overwhelmingly used the most among vaccines. if you ask cases protected against the study showing the two doses of pfizer are about 79% protective. symptomatically disease, two doses of pfizer, 88%. hospitalizations again in england, two doses, 96% real world effectiveness. you can make a reasonable assumption that these are applicable -- data act liberal -- that data applicable to pfizer is applicable. what about the j&j vaccines? there is indirect and direct evidence for effectiveness of j&j against the delta variant. because if you look at a comparison between the j&j and the oxford astrazeneca, because they use similar adenovirus vectors, we have clinical data with az in real world effectiveness. real-world infection versus symptomatically, versus the important number on the bottom of the slide, a 92% effective against hospitalization from the delta variant. there's also other types of data. mainly looking the antibodies that are produced by vaccination -- produced by vaccination from j&j. they looked at studies with a typic

most public health experts say a third shot of pfizer's mrna vaccine is not necessary for most adultsswitzerland, the head of the world health organization slammed the growing vaccine gap between rich and poor countries. this is dr. tedros adhanom ghebreyesus. >> some countries and regions e actuallyrdering millions of booster doses before otr countries have had suffice to vaccinate their health workers and most vulnerable. we are making conscious choices right now not to protect those most in need. amy: meanwhile, the u.s. food and drug administration has added a new warning to johnson & johnson's single-dose covid-19 vaccine. the fda reports about 100 cases of the rare autoimmune disorder guillain-baÉ among 12.8 million j&j vaccine recipients in the u.s. the cases were mostly in men aged 50 and older, with one death reported. the fda said in a statement the benefits of the vaccine still clearly outweigh the risks. for more, we're joined in palo alto, california, by dr. abraar karan. he is a fellow at stanford university in the division of infectious diseases and geographic medicine.

these are mrna vaccines. theoretically it makes sense. i do not think that the average person needs to worry about that. if you do have any particular condition, talk with the doctor about it. >> is it unethical, because i have heard people talk about since we do not have a supply issue now in this issue, that is not true for the rest of the world, why not go out and get the others as well because if i am less likely to get sick, less likely to transmit it, aren't i helping my society by using less resources from a medical standpoint? >> i think it is overkill, especially looking at the community you are in. if we are in vermont or san francisco where there is a very high vaccination rates, don't think it's necessary to do it. just like i think it is not necessary to wear a mask when you're walking outside. >> as far as unethical, i would not say it is unethical, i will say it is necessary. the ethical issue that we are hoarding the vaccines and they're not going throughout the world. i do not think that this will promote the sharing of v

but there has not been any with the mrna. they're going to put a warning label for guillain-barre on the packaging. >>> in the meantime, thank you for joining us today, we appreciate your insight. >>> coming up next, the billionaire space race is on. what about space tourism? we will talk about that. ufos and planets aligning. we wi hey, i just got a text from my sister. you remember rick, her neighbor? sure, he's the 76-year-old guy who still runs marathons, right? sadly, not anymore. -what, you mean-- -mhm. -just like that. -wow. so sudden. um, we're not about to have the "we need life insurance" conversation again, are we? no, we're having the "we're getting coverage so we don't have to worry about it" conversation. so you're calling about the $9.95 a month plan -from colonial penn? -i am. we put it off long enough. we are getting that $9.95 plan, today. (jonathan) is it time for you to call about the $9.95 plan? i'm jonathan from colonial penn life insurance company. sometimes we just need a reminder not to take today for

. >>> while covid cases climb now information about just how critical the second mrna vaccine dose really is where in the bay area people aren't getting fully vaccinated. >>> the lights are on now at the coliseum, but we're less than 24 hours away from a city council meeting that could factor into the a's decision to possibly leave the area. >>> heat eases the next few days. i'll show you how much cooler coming up. abc7 news at 11:00 starts right now. >> building a better bay area moving forward finding solutions, this is abc7 news. >>> for most people who get this delta variant it's going to be the most serious virus they get in their lifetime. >> tonight experts sound the alarm as covid cases are spiking. the delta variant is ripping through unvaccinated communities all across the country. good evening. thank you for joining us. i'm dan ashley. >> i'm ama daetz. as cases surge one bay area organization is facing a unique challenge. abc7 news reporter and vaccine team member kate larsen reports on the growing number of people skipping their second vaccine dose. >> we've had a lot of peop

the mrna technology would turn out to be foundational for many more things over time.ed that you can turn around and ask for information and just have it at your fingertips. so, i think technology's profoundly influencing everything we do. i want to end by asking a couple of big picture questions about the future. what do you think is the biggest challenge facing us? i would define climate change as a clear thing we can all focus on because it's something we are leaving behind for the next generation. i think our generation will navigate through it, but it's what we leave for the next generation. so, it weighs on me. so ways in which you need to act early, before the warning signs fully appear. and they're appearing now. before the actual events play out. like covid, except you had to make all the right decisions many years before it actually hits you. and so i think it's one of the more important challenges of our lifetime. people always want to know about the personal technology habits of those who run big technology firms. i'm going to ask you about some of your hab

does a sick vibrato] ♪ >>> while covid cases climb now information about just how critical the second mrnacine dose really is where in the bay area people aren't getting fully vaccinated. >>> the lights are on now at the coliseum, but we're less than 24 hours away from a city council meeting that could factor into the a's decision to possibly leave the area. >>> heat eases the next few days. i'll show you how much cooler coming up. abc7 news at 11:00 starts right now. >> building a better bay area moving forward finding solutions, this is abc7 news. >>> for most people who get this delta variant it's going to be the most serious virus they get in their lifetime. >> tonight experts sound the alarm as covid cases are spiking. the delta variant is ripping through unvaccinated communities all across the country. good evening. thank you for joining us. i'm dan ashley. >> i'm ama daetz. as cases surge one bay area organization is facing a unique challenge. abc7 news reporter and vaccine team member kate larsen reports on the growing number of people skipping their second vaccine dose. >> we've h

a cure on this mrna platform?verything is going in our favor but this is crucial to our american people and the american economy and manufacturers, that we will put them somewhere in a system that is sustainable for the future. i thank you for this new to me and i think the chair and i yelled back -- yield back. >> that will end our hearing for the day. i went to thank all of our colleagues. thank you for such a thoughtful discussion about our ongoing response to this pandemic and the path forward. with that, for any senators that wish to ask additional questions, questions will be due in two business days, august 3 at havoc rpm. the committee will next meet tomorrow. this is the general counsel. and when will cox and david prouty -- gwen wilcox and david pouty. thank you to everyone. >> c-span is your unfiltered view of government. funded by these television companies and more. buckeye broadband supports c-span as well as these other television providers, giving you a front row seat to democracy. >> here is some

tell us how you think mrna can succeed here when we've seen so many try and fall short in malaria. >>or having me mrna technology has experienced a baptism of fire with the covid-19 pandemic and the success of being able to develop a vaccine there. and this context we have learned a lot how to use this technology to address difficult pathogens with regard to inducing very important immune response. and we think that this potency of inducing a response can be also used against the malarian pathogen this together with the fact that it could show that the manufacturing can be upscaled easily and development is fast is very good path forward also for malaria. >> another part of your efforts here in malaria are to establish vaccine manufacturing production in africa. there has been so much focus on this in terms of vaccine access for covid-19 what is the pace of being able to establish this manufacturing footprint there and could it help with covid? >> yes, absolutely in principle, it's sort of the contrary the covid-19 vaccine driven establishment of manufacturing cap capacities in the af

if they have doses of astrazeneca and they're going to get doses of an mrna vaccine, they no longer have to wait until they have both doses, right? the full vaccination schedule for their population, they can move ahead with what they have in their fridges and then if they get a different vaccine for the second dose, that's going to be fine. and i think really, paula, the other takeaway from this news is this is the strongest recommendation we have seen yet in favor of mixing and matching vaccines. i mean, yes, canada has done it and said that it could happen. now germany is saying that it should happen. angela merkel, like justin trudeau, has mixed and matched her vaccines. look, i'm no scientist, but what's happening here is we've known since the beginning that these -- the different vaccines operate differently, right? they work on different platforms. and the astrazeneca vaccine is what's known as an adenovirus vaccine. the moderna or pfizer vaccines are mrna vaccines, and they trigger an immune response in slightly different ways. there is now a growing body of evidence that if you

so get the mrna vaccine. frankly the j j remains a good vaccine in the risks of it are exceedingly rare shot to really quickly and could is we do need to look to wrap here. >> what about the the booster shot pfizer talking about. getting a shot after a year. >> today. there is no evidence that we need a booster shot for otherwise healthy people who have been vaccinated, whether that will change in the next months or 3 months or 3 years. it's it's looking into a crystal ball, but no evidence right now that it's necessary. >> thank you. all right. right. appreciate it. that is doctor john swartzberg, professor emeritus of public health at u c berkeley. thanks, doctor. thank you for sharing your have a good evening. stay up to date on the latest covid-19 information. use your smart phone and scanned the qr codes on your screen there. >> it will take you directly to our coronavirus section at kron 4 dot com. >> still to come tonight snatched from their own whole of the lake. couple discusses their kidnapping in t

the mrna technology would turn out to be foundational for many more things over time.hat you can turn around and ask for information and just have it at your fingertips. so, i think technology's profoundly influencing everything we do. i want to end by asking a couple of big picture questions about the future. what do you think is the biggest challenge facing us? i would define climate change as a clear thing we can all focus on because it's something we are leaving behind for the next generation. i think our generation will navigate through it, but it's what we leave for the next generation. so, it weighs on me. so ways in which you need to act early, before the warning signs fully appear. and they're appearing now. before the actual events play out. like covid, except you had to make all the right decisions many years before it actually hits you. and so i think it's one of the more important challenges of our lifetime. people always want to know about the personal technology habits of those who run big technology firms. i'm going to ask you about some of your habits.

that is the two mrna vaccines, montana and the j&j faxing which is a human adenovirus vaccine. as i mentioned to this midi on prior hearings, the clinical trials that proved extraordinary applications must of these vaccines to the tune of 93 and 94% are very clear right now. what i would like to emphasize today is what transpired last hearing that is an accumulation of data on the real-world effectiveness of these vaccines in a situation we are confronted a historic pandemic. not only in the united states but also inn the uk in the form of england and scotland, israel and other places. when the one folks at the data, one good example is the cohort study from israel in which the m rna faxing use in that population was highly effective in the real world beyond clinical trials including among asymptomatic from early symptomatic advanced disease, intensive care and even death. across the cohort, you saw that it was effective essentially every age group from young individual, middle-aged and even the elderly. let us the good news. the sobering news you've heard of is the fact that w

booster -- meeting an -- needing an mrna booster? that data -- that article you reported on was not peer-reviewed. it was a test tube study that looked at one level of protection. when you consider the data we have, we are looking at all the different antigens -- the antibodies, i should say, neutralizing antibodies, as well as cell activity, so the complete protective response. that is much more valuable than what this for work which came out last night indicates. i think we have to caution everyone just to rely on health officials who have all of this data at their disposal. they have not declared if or when a booster may be needed for any of the vaccines at this point. shery: joseph wolk speaking with our colleague, alix steel. be sure to tune into bloomberg radio, broadcasting live from our studio in hong kong. 20 more ahead. stay with us. -- plenty more ahead. stay with us. ♪ shery: almost every day, we are getting more headlines on china evergrande, the world's most embedded developer. continue to see stocks and dollar bonds un

you have state run economies you don't have glorious competition and that's where the mrna vaccine camem. we have 20 seconds are you worried about the immunity where they haven't been subjected to other viruses? >> not particularly. we are likely going to see them come back or that taking care patients have had this and i don't think there'll necessarily be a major problem. something will be able to handle but it's a sign of normalcy. kennedy: i have tendinitis in my elbow. what do you think? excise it having you on. thank you so much. >> thank you for having me. former president jump tomorrow heading to florida. will his trolling force the biden administration to do something? i'm in studio with answers and appetizers, next. kills plaque bacteria at the gum line to help keep the gum seal tight. new parodontax active gum repair toothpaste. kennedy: former president donald trump into the u.s.-mexico border but u.s.-mexico border says kamala harris only be in there because he announced he was going first. watch. >> kamala harris your vice president only went -- to the border yesterday for

the decade of investment we saw in mrna, in what we now see as crispr development has helped us havekthroughs when it comes to the vaccine. what in terms of knowing our proteins, what is that going to lead to? push us forward five or 10 years. sujal: i think that we should celebrate enormous accomplishments the scientific community has delivered with mrna vaccines and with the response to the covid-19 pandemic. over the course of the last couple of decades, the rate of new drugs being approved by the fda has not significantly increased. during that two-decade period, the expand in research and development at pharmaceutical $eáÑ quadrupled. if you look at what is going on today, biofarma has picked off many of the drugs were common elements and they need machine learning to figure out what are the differences, how do i build a better therapeutic? the promise of the technology we are working to bring to the world is that, you will be able to build better therapeutics in less time, with higher efficacy and less toxicity. caroline: we are looking at a chart of your share price, you recen

on the other hand we haven't seen it with the mrna vaccines.ked and we will -- put very rare with johnson and johnson. rare with mrna vaccines will have their own rare side effect. >>> the concorner is for those who aren't fully vaccinated. could pushing for a booster slow down the campaign do you think? >> i actually do. what i'm concerned about is if we talk too much about boosters and also if we talk about the vaccines not working against the delta which it does. you can discourage people from getting the vaccine who need a second dose or wouldn't haven't gotten two doses because the point is that these two work. there was a lot of talk about boosters, i think that was put aside yesterday by dr. fau ci and the fda. not forever but the point is right now it doesn't seem like it's indicated. we have strong immune responses. you just said there's rare side effects. getting a booster on top of a second dose when it's not needed is not indicated and what we should focus on is getting people vaccinated who are reluctant to take it and work on that

i also cried the day my parents received their second mrna vaccine. because for me vaccines represent love. my grandfather was a united states navy man. i was his tags on the desk with me today. he used to tell stories about total eeo. my mother too remembers the relief when her family stood in life for that vaccine. vaccines are acts of love made possible by innovation. and i believe that in innovation we have historically seen the best of america. that is where we are exceptional. from skyscrapers to airplanes eventually landing on the moon we are innovators and the covid vaccine in my opinion is our generation's shot at a moon landing. this is a step for humankind made possible by science. two of the largest groups of unvaccinated people existing in communities you've mentioned, communities of color and rural populations. there have been concerted disinformation and misinformation campaigns to discourage communities including these from vaccinating themselves against covid-19. we cannot allow people dubbed a threat to this nation by our own intelli

the eu was lowered to vaccinate but they also vaccinated more with the mrna vaccine, which could leadsmission. the negative story at the eu level in the beginning of the vaccination campaign could turn into a positive story if they see less cases because they have so many people vaccinated with the more effective mrna vaccine. in terms of total number, they are picking up. they will be at thev"Ñ0■ place e the u.k. is. probably three or four weeks behind. it does add some risk. it does mean the virus will find more unvaccinated people to send to the hospital but ultimately it is possible the eu story turns more positive due to the kinds of vaccines they are using than the u.k. story. taylor: is greek letter day as we learn about delta, an alpha variant. i am thinking post delta. does it become like the flu where every season there is a new rotation, or too soon to tell? scott: we definitely see lots of mutations, lots of new variants in 2021. it is somewhat natural that the virus becomes more transmissible over time. there is speculation that over time the virus becomes less lethal bec

issue whether they will be able to get some of that supply as well, the mrna vaccines.ad: i'm going to keep the vaccine topic going. the rollout slowly in southeastern asia is what we are talking about. there is a widening gap between countries that use the messenger rna vaccine, pfizer and moderna, and others like astrazeneca, which are more traditional. and the rollout at the speed of continental drift in africa, basically. yvonne: you have to wonder how you bridge that gap, because you are seeing when it comes to even covax -- chinese drugmakers are trained to help fill in some of these gaps with the vaccine, the shortages they have been dealing with. more of these countries are getting access to these, you could argue, less potent types of vaccines. so you are seeing a two-tier pandemic going on. david: take a step back. this is normally a process that takes years, if not decades. we have shrunk the timetable from when we got the virus to now, billions vaccinated in about 16 months. the question also is data. are we looking at proper data? do we have enough data to

vaccines, and there are reports that mrna vaccines are less effective than the delta variant.ination program is picking up slowly. they are averaging less than a million people per day. at that pace, it is going to be taking a couple of years before they vaccinate the whole population. i hesitate to compare it to what happened in india last year, but it's got comparative issues. it is an uncontrolled situation and shows how problematic they delta variant is and how problematic the slow vaccination programs are going to be for emerging markets around the world, and they are highlighting concerns about non-mrna vaccines that may be applicable to highly developed market economies that have done a great job with the vaccination programs, and the u.k. is one of those. anna: fully vaccinated britons will no longer need to isolate when they return home from burdened countries. it is a relaxation and the rules -- in the rules from july 19. it will offer a boost to the ailing travel industry, which has struggled with on and closed border. running is is wizz air ceo jozsef varadi. good

researchers says a dose of the astrazeneca vaccine and mrna vaccines which is pfizer and moderna canesponse. this idea of mixing and matching, it seemed at first it was being proposed out of necessity. now it might actually be preferable. what's behind this? >> reporter: yeah. absolutely, kim. this is the strongest recommendation we've seen in the world for mixing and matching vaccines. some have done it, as you say, out of necessity. here it wasn't the case in europe when there were safety concerns over the astrazeneca vaccine and some under 50s, under 60s who had received a first dose of that were then advised to get a dose of a different vaccine such as pfizer. that was out of necessity. canada said based on scientific evidence we could mix and match. now germany is saying we should mix and match. angela merkel, the german chancellor, has done just that. i know scientists. what our viewers need to know is this. there are different vaccine platforms, different technologies that trigger your immune system in different ways. they are founding now almost incon throw verse bring that i

ideally with high efficacy vaccines, with mrna vaccines and with j&j. there is a big debate with people who are immunocompromised should be boosted. folks living with h.i.v. would fit into that category. stephen: maureen and adeeba, did you have thoughts? maureen? adeeba: i did. i think we use the platform to kind of call out for the scientific community to do more -- to really reinvigorate just as we did at previous aids conferences for anti-viral therapy. i truly do think, particularly with the variant that's raging around the world, experiencing that in malaysia. for asia, we're doing quite well in terms of vaccination. but still we're not able to catch up in many states around malaysia because of vaccine supply and number of infections and deaths skyrocketing. so perhaps as the -- what the h.i.v. community is so well-known for, perhaps we need to make it stronger for vaccination across the world. maureen: i think one of the advantages of the mrna approach you can tweak this with a lot more ease than the traditional vaccine platform. i think to that

i'm referring to pfizer, moderna work with mrna. they create a it does not alter your genome sequence. >> can receiving the covid-19 vaccine cause you to be magnetic. >> we saw that viral video of the woman placing the fork on her body and it sticking. no. there's no proof of this at all. >> does any of the covid-19 authorized for use shed or release any of their components >> this is referring shedding. this is a popular misinformation. antivaxers saying, hay, stay away from people or vaccinated. they'll shed a live virus. they weren't afraid of it before. here's the thing. it does not contain a live virus. it doesn't infect you with covid-19. so that's totally false. >> is it safe to get a covid-19 vaccine if i want to have a baby some day. >> you are safe. there's no evidence at all, no real, real data or lab evidence that this can affect your fertility. in fact, many people in the trials went on pregnant sis. a lot of people in the world have gone on with no issue at all. there's no way this vaccine is going to cross over and al

another compelling reason for the stock to be trading at rich valuations and that is really using the mrnarocess and there is a reason why it is better, but that process is probably at least three to four years away from generating substantial revenues and mike's trade structure, that is great for using this. it is 3% of the stocks value, but timing these things are very tricky the stock even if it is to trade sideways, and he went all of the way out to october so buy quite a bit of time to wait for a potential correction. and then as he continues to collect premium on the short leg of the put diagonal he can potentially buy himself more to the downside >> mike, we'll give you the final word on this >> i think that is one of the important points, too. there is a lot of good news, but a lot of that is already known i think we're running out of those. that is one of the reasons i think it could take a rest or a downturn here. >> coming up next from silver to gold answering your twitter questions next, stay with us it's a thirteen-hour flight, that's not a weekend trip. fifteen minutes until

involve your body taking a little althat gets injected that helps you code for the spike protein, either mrna or dna in the case of johnson & johnson. you code it up, meaning you create a protein out of it and raise an immune response. your body is like what, this is weird. this looks foreign to me and i'm going to make an immune response against it. that's how our vaccines it's important because these mutations have pro teens. >> where does the word plus come from as part of the name? is that standard naming this but a little more dangerous? what is it, really? >> i don't know why this becaus transmissible than the delta variant. >> but we do know the delta variant is more france missable. so giving that, talk about the three in vaccines that are available to us in the u.s. and how effective they are against the delta variant. >> you're right, it's transmissible. there's johnson & johnson, moderna and pfizer. all three put out evidence that they make what are called neutralizingd would dis. johnson & johnson did just last week. that's one level. second, is that three all produce t cells and

that is one of the advantages the mrna vaccines offer because they can be updated so quickly.ght come online. that would be exciting if that happened. yvonne: what do you make of mixing vaccines? >> i think there is a lot of potential but we have not tested it. i think it is a missed opportunity because when biontech was made, the developers look at biontech versus -- biontech plus plan tech nobody has looked at them. with astrazeneca, with other vaccines. immunol logic, there could be advantages. we cannot recommend it until it has been tested. i am not keen of the idea in thailand where they said sinovac plus astrazeneca. that has not been tested. we think it should work but it needs to be tested first. yvonne: you advise the hong kong government. we just reached 2 million when it comes to fully vaccinated hong kong people. what else till needs to happen? >> we need a clear plan of what is going to happen and when. are we looking to stay with zero covid for another year or two years or are we looking to start living with the virus at some point? we have heard singapore talki

what your most excited about, and are you investing in mrna? that's sort of the breakthrough technology right now >> yeah, so we are, of course, watching mrna but interestingly, the next big approval we hope to have soon in the united states is for a small interfering rna to treat patients who had a prior heart attack we're very excited about this. this could be one of the biggest medicines novartis has had the potential is to treat those who have had heart attacks and their cholesterol is not rnd control. what's magical about this using rna, small interfering rna technology is you only need to take it twice a year and see up to a 60% reduction in your cholesterol. this leads to significant benefits a major program ongoing soon hopefully to be launched in the united kingdom to take on cholesterol lowering and we're working to do that in the united states a multibillion-dollar opportunity for the company p.vas, thanks for joining us >> thank you both. take care. >>> when we come back -- jpmorgan giving jamie dimon an incentive to stay at the com

dose because delta does overwhelm a single dose only of the mrna vaccines. >> that's right.he time to go out is right now because it's going to take time for that full vaccination effect to kick in. one of the big remaining questions about the coronavirus right now is whether vaccinated people can transmit the virus to others. we're hearing this question all the time. with that uncertainty looming, how do we best protect ourselves and our loved ones, do you think? >> no vaccine is 100%. these vaccines are astonishingly effective, but they're not perfect. that means with 162 million fully vaccinated people, we're going to see some breakthrough cases and tragically some of those will be severe, some may even result in death, and some of those may result in a spread of covid. that doesn't change the reality. the almost line, the plain truth, is that getting vaccinated is your best way to avoid serious illness and death and your best way to reduce the risk that you'll spread the infection to others who could themselves get seriously ill or die from it. >> and, dr. friedman, heal

i expect that the mrna data, the vaccine data from pfizer and moderna is going to show really good efficacye younger populations. those children in schools are going to be the critical thing right now as we think about the fall. we expect to see a bit of a surge in the fall anyway as people move more indoors and schools are going to be an environment where the virus spread could be maximized. it is great to see the data showing that kids are less susceptible to severe disease, but they are not resistant to disease so we have to think about protecting those populations, especially if we are going to put them in situations where virus spread is going to be optimal. jonathan: what would it take for you to endorse the position of individual responsibility and move away from these broader societal measures? andy: i think it comes down to vaccination. i cannot stress enough how wonderful the data is on vaccine safety and efficacy with these covid-19 vaccines. they are successful beyond the wildest dreams of any clinician or scientist would have said a year ago. we have to find a way to get this i

the israeli data conflicts with other data that shows the immunity may last for years and that the mrna vaccines in particular are very effective against the delta veterinarian. -- variant. >> when israel made this report, the actual numbers of people involved was very small. that was one thing to note about the report, that there wasn't a huge volume of people who they were basing this report on. >> right. and i don't think we even know what the report exactly is. as in, we still don't know, is it modelling studies, what are they basing their numbers on? part of the problem is that here in the u.s., we don't have our own numbers, because the cdc stopped tracking mild and asymptomatic breakthrough infections, which is a big mistake, because what we really need to know at this point is what is happening with breakthroughs, who is getting breakthrough infections. is it people who have got the vaccine earlier on? so is immunity actually waning? is it all the delta variant? also, are people getting breakthrough infections, so they're vaccinated, and still getting infected, do they have long

the distribution in europe of the mrna vaccine really has been lagging.ctations in continental europe is below where we would like to see it. jon: the airlines have suffered because of that, and the cyclical story in many ways sector to sector, the airlines have peaked. in the minds of some people, they are struggling. the banks are starting to struggle as well over the last month. but what's interesting is that you turn to your process, and for the following question, i am far more interested in the process. the debate right now on the cyclicals is the debate it has been over the last six months. is it just a short-term reopening trade, or some thing more durable, something more sustainable? what is your process to distinguish between the two things? what are the signposts you look for? abby: we are also looking at the idiosyncratic opportunities because just because a particular company happens to be in a particular sector or industry according to the s&p definition doesn't tell us as much as we need to know, so we are looking at how individual come an

ideally one of the mrna vaccines made by pfizer, biontech or moderna. what do you hear about that, dr. sax, what would you say to a patient who came to you and said i got the johnson & johnson vaccine or somebody who came to you for advice and should i get a booster. >> the official guidelines are not to get a booster. on the other hand, we have had concerns about the j&j vaccine for some time, and there's quite a bit of chatter in the scientific community that this may be necessary, driven not just by the data that you mentioned, which have not been peer reviewed but by studies who have shown people who have received a vaccine, either the j&j vaccine or the astrazeneca vaccine, and if they receive an mrna vaccine, they have a tremendous boost to the strength of their vaccine, so it would not surprise me if ultimately there is a recommendation, especially with delta circulating for the mrna vaccines to follow the j&j vaccine, but we'll have to see. >> and just really really quickly, dr. sax, where do you stand on somehow people showing that they have re